US Regulatory Affairs Market Size, Share and Trends 2026 to 2035
US Regulatory Affairs Market (By Services: Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services; By Category: Drugs, Biologics, Medical Devices; By Indication: Oncology, Neurology, Cardiology, Immunology, Others; By Stage: Preclinical, Clinical studies, PMA; By Service Provider: In-house, Outsourced; By Company: Small, Medium, Large; By End User: Medical Device Companies, Pharmaceutical Companies, Biotechnology Companies) - Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2026 to 2035
Get a Sample
Table Of Content
US Regulatory Affairs Market Size and Forecast 2026 to 2035
The US regulatory affairs market size accounted for USD 4.31 billion in 2025 and is predicted to increase from USD 4.64 billion in 2026 to approximately USD 9.02 billion by 2035, expanding at a CAGR of 7.66% from 2026 to 2035. The market growth is attributed to increasing regulatory complexity, expanding healthcare innovation, rising FDA submission volumes, and growing adoption of AI-enabled regulatory technologies.
Key Takeaways
- By service, the regulatory writing and publishing segment held the largest market share in 2025.
- By service, the legal representation segment is expected to grow at a remarkable CAGR during the forecast period.
- By category, the drugs segment held the largest share of the United States regulatory affairs market in 2025.
- By category, the medical devices segment is expected to grow with a notable CAGR between 2026 and 2035.
- By indication, the oncology segment held the highest share of the market in 2025.
- By indication, the immunology segment is expected to grow at the fastest CAGR during the forecast period.
- By stage, the clinical studies segment held the highest share of the market in 2025.
- By stage, the PMA segment is expected to grow with the fastest CAGR during the forecast period.
- By service provider, the outsourced segment held the largest share of the market in 2025.
- By service provider, the in-house segment is expected to grow rapidly between 2026 and 2035.
- By end user, the pharmaceutical companies segment held the largest market share in 2025.
- By end user, the biotechnology companies segment is expected to grow at a remarkable CAGR during the forecast period.
Market Overview
The United States regulatory affairs market is fueled by growing regulatory complexity in several industries, particularly in pharmaceuticals, biotechnology, and medical devices. Regulatory affairs technology encompasses regulatory submission software and services, compliance management, regulatory labeling, and regulatory intelligence.
These solutions support the companies in handling changing requirements and speeding up product approvals in regulated healthcare industries. In 2025, the FDA's Center for Drug Evaluation and Research approved 46 novel drugs, loading up the agency's workload. The market continues to be propelled by increasing regulations, integration of AI, and innovation in products.
Impact of Artificial Intelligence on the United States Regulatory Affairs Market
Artificial intelligence (AI) tools are starting to serve regulatory affairs teams well in the review of guidance documents and in handling voluminous data in submissions. These platforms can automate the manual workload and enhance the accuracy of regulatory submissions.
In January 2025, the FDA published draft guidance on AI models in drug and biologic submissions. This movement extends beyond the regulatory realm to embrace the transformative potential of AI in the broader context of regulatory decision-making and development. AI is being integrated further into regulatory platforms by software companies like IQVIA, Veeva Systems, Oracle Health, Medidata, and ArisGlobal.
Market Report Coverage and Key Metrics
| Report Coverage | Details |
| Market Size in 2025 | USD 4.31 Billion |
| Market Size in 2026 | USD 4.64 Billion |
| Market Size by 2035 | USD 9.02 Billion |
| Market Growth Rate from 2026 to 2035 | CAGR of 7.66% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Services, Category, Indication, Stage, Service Provider, Company, and End User |
Market Dynamics
Drivers
Increasing Regulatory Complexity Across Healthcare Industries
Increasing regulatory complexity across the pharmaceutical, biotechnology, and medical device sectors is expected to drive the market. This growth likely leads to a continued demand for services and technologies for regulatory affairs in the pharmaceutical, biotechnology, and medical product sectors. Furthermore, the rising pharmaceutical and biotechnology innovation is projected to increase regulatory workloads and strengthen demand for regulatory affairs expertise.
Restraint
High Regulatory Compliance Costs
High regulatory compliance costs are expected to remain a significant challenge for healthcare organizations, thus hindering the market. During product development programs, smaller and medium-sized pharmaceutical, biotechnology, and medical device companies are likely to be under more financial stress. Regulatory changes drive up training/facilities costs and can lead to process changes and system upgrades.
Opportunity
High Demand for Faster Product Approvals Encouraging Investment in Regulatory Efficiency Solutions
High demand for faster product approvals is estimated to increase investment in regulatory efficiency solutions, further creating immense opportunities for the market. Pharma and medical technology companies value round-the-clock turnaround in the submission process and ensure optimal product launch strategies. Furthermore, the Surging medical device development and digital health innovation are likely to expand opportunities for regulatory affairs technology providers and service organizations.
Market Segmentation Analysis
Service Insights
The Regulatory Publishing and Writing Segment Dominated the Market in 2025
The regulatory publishing and writing segment dominated the United States regulatory affairs market in 2025 due to the rising complexity of regulatory pathways across pharmaceuticals, biologics, and medical devices. Companies can save money and time by outsourcing their regulatory publishing and writing, enabling them to focus more on regulatory approval and marketing.
The legal representation segment is expected to grow at a remarkable CAGR from 2026 to 2035, driven by the increasing volume of regulatory disputes, enforcement actions, and compliance-related legal requirements. Companies advance their legal preparations for adjusting to changing federal and state regulations. Regulatory attorneys have an important part to play in the review of promotional practices, label claims, and market access strategies.
Category Insights
The Drugs Segment Dominated the Market in 2025
The drugs segment dominated the United States regulatory affairs market in 2025 due to the extensive regulatory requirements associated with pharmaceutical development, approval, and lifecycle management. Furthermore, the gains have led to ramped-up submission activity, regulatory regimen, compliance requirements, and lifecycle management obligations across the entire pharmaceutical industry.
The medical devices segment is expected to grow at a notable CAGR between 2026 and 2035, supported by the rapid expansion of digital health technologies, connected devices, and software based medical products. Product classification, quality management systems, cybersecurity documentation, and market authorization compliance demand special expertise from device developers in order to meet regulatory standards.
Indication Insights
The Oncology Segment Dominated the Market in 2025
The oncology segment held the largest United States regulatory affairs market share in 2025 due to the high volume of cancer drug development programs and regulatory submissions across the healthcare industry. In the United States, around 2 million new cancer cases are estimated to be diagnosed in 2025, a need for sustained innovation in cancer therapeutics. The growing adoption of targeted therapies, antibody-drug conjugates, and cell-based treatments has increased regulatory documentation requirements.
The immunology segment is expected to grow at the fastest CAGR between 2026 and 2035, supported by greater regulatory momentum related to a new generation of immune-targeted therapeutics and biosimilars. Complex submission needs, including biologic manufacturing, immunogenicity testing, long-term assay of efficacy, and safety monitoring, are all supported by regulatory teams.
- According to the National Institutes of Health (NIH), autoimmune diseases affect an estimated 15 million people in the U.S
Stage Insights
The Clinical Studies Segment Dominated the Market in 2025
The clinical studies segment contributed the biggest United States regulatory affairs market share in 2025, as there is a heavy burden of regulatory activities to be completed during clinical development. Regulatory professionals were heavily recruited by pharmaceutical, biotechnology, and medical devices companies to assist in the design of studies, development of study protocols, regulatory submissions, amendment of studies, and safety reporting.
The PMA segment is expected to grow at the fastest CAGR between 2026 and 2035, driven by new and innovative implantable devices, cardiovascular innovations, neuromodulation systems, robotic surgical platforms, and AI-enabled medical products designed to meet stringent regulatory compliance standards. These are creating a major need for specific regulatory skills and submission management services.
Service Provider Insights
The Outsourced Segment Dominated the Market in 2025
The outsourced segment led the United States regulatory affairs market in 2025, as healthcare organizations look for external assistance in complex and intricate regulatory work. The increased use of digital transformation business models further bolsters demand for outsourced regulatory affairs services within the healthcare industry.
The in-house segment is expected to grow at the fastest CAGR between 2026 and 2035, driven by increasing product portfolios and global efforts to register these, which were also reflected in the fact that large healthcare firms increased their regulatory departments. These factors strengthened the leadership of the in-house segment in the industry.
End User Insights
The Pharmaceutical Companies Segment Dominated the Market in 2025
The pharmaceutical companies segment dominated the United States regulatory affairs market in 2025, driven by extensive regulatory involvement throughout drug discovery, clinical development, commercialization, and post-market monitoring. Pharmaceutical companies need distinct regulatory assistance to initiate the development in investigational use, prepare for manufacturing compliance, and report any safety concerns of a product.
The biotechnology companies segment is expected to grow at the fastest CAGR between 2026 and 2035, as new highly innovative products with rigorous regulatory monitoring are being developed. The production of these products can be highly complicated; the trials used to fabricate them must be designed in a specialized manner, and numerous clinical trials may require significant regulatory paperwork.
United States Regulatory Affairs Market: Country-Level Analysis
Why Did California Dominate the United States Regulatory Affairs Industry in 2025?
The Californian market is growing due to its unmatched concentration of life sciences companies, research institutions, and healthcare technology developers. The state is home to great innovation hubs, including San Diego, South San Francisco, San Francisco, Irvine, and Los Angeles, thus ensuring a substantial need for regulatory consulting and compliance services. These factors bolstered demand for regulatory intelligence platforms, submission management solutions, and regulatory consulting services for the entire state.
Why Is Massachusetts Emerging as the Fastest-Growing State in the United States Regulatory Affairs Industry?
Massachusetts is considered to be a significantly growing area, supported by its globally recognized biotechnology ecosystem centered in Boston and Cambridge. The Massachusetts Biotechnology Council (MassBio) estimates that the Commonwealth has a significant demand for regulatory expertise across advanced therapeutic areas, with more than 1,700 existing biotechnology companies.
United States Regulatory Affairs Market Value Chain Analysis
- Regulatory Intelligence & Compliance Monitoring
Regulatory requirements, guidance updates, and compliance standards are collected and analyzed to support healthcare product approvals.
Key Players: FDA, EMA, MHRA, RAPS, DIA, ArisGlobal.
- Regulatory Strategy & Submission Preparation
Regulatory data, technical documents, and clinical evidence are compiled into submission-ready regulatory dossiers.
Key Players: IQVIA, Parexel, ICON plc, Medidata Solutions, Certara.
- Post-Approval Compliance & Lifecycle Management
Approved products require ongoing regulatory monitoring, labeling updates, safety reporting, and compliance management.
Key Players: Veeva Systems, MasterControl, TraceLink, IQVIA, ArisGlobal.
Market Competitive Landscape: Leading Companies and Strategies
The United States regulatory affairs market is moderately consolidated, with established technology providers and consulting firms holding strong positions. IQVIA, Veeva Systems, Oracle Health, ArisGlobal, Parexel, ICON plc, and Medpace are some of the leading companies. Companies are making investments in building capacities for biologics, cell therapies, gene therapies, and digital health products. The need for regulatory knowledge is still growing in the bio- and medical product and pharmaceutical industries.
Strategic investments and technology innovation continue to reshape the competitive environment. Parexel enhanced regulatory consulting programs that run through advanced development in therapeutic fields. ICON plc made investments in the integration of regulatory and clinical development services. Furthermore, the growing AI adoption and rising submission volumes are expected to intensify competition over the coming years.
US Regulatory Affairs Market Companies
- WuXi AppTec
- ProPharma
- PharmaLex (Cencora)
- Medpace
- iuvo BioScience, LLC.
- IQVIA, Inc.
- ICON plc
- Genpact
- Freyr
- Charles River Laboratories
- Accell Clinical Research, LLC.
Recent Development US Regulatory Affairs Market (2025-2026)
- In June 2026, Bloomberg Industry Group acquired Regology, an AI-powered regulatory intelligence platform, enhancing its capability to assist organizations in navigating regulatory changes more efficiently. This acquisition expands Bloomberg's portfolio of law, tax, and government affairs solutions by integrating AI-driven regulatory change management, enabling organizations to identify emerging risks, assess their impact, and adapt to evolving requirements. (Source: https://finance.yahoo.com)
Segments Covered in the Report
By Services
- Regulatory Consulting
- Legal Representation
- Regulatory Writing & Publishing
- Writing
- Publishing
- Product Registration & Clinical Trial Applications
- Other Services
By Category
- Drugs
- Innovator
- Preclinical
- Clinical
- Post Market
- Generics
- Preclinical
- Clinical
- Post Market
- Innovator
- Biologics
- Biotech
- Preclinical
- Clinical
- Post Market
- ATMP
- Preclinical
- Clinical
- Post Market
- Biosimilars
- Preclinical
- Clinical
- Post Market
- Biotech
- Medical Devices
- Diagnostics
- Preclinical
- Clinical
- Post Market
- Therapeutics
- Preclinical
- Clinical
- Post Market
- Diagnostics
By Indication
- Oncology
- Neurology
- Cardiology
- Immunology
- Others
By Stage
- Preclinical
- Clinical studies
- PMA
By Service Provider
- In-house
- Outsourced
By Company
- Small
- Medium
- Large
By End User
- Medical Device Companies
- Pharmaceutical Companies
- Biotechnology Companies
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Frequently Asked Questions
Ask For Sample
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
sales@precedenceresearch.com
+1 804-441-9344
Schedule a Meeting